← All trials
NCT04906434
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 26, 2020
- Primary completion
- Oct 31, 2022
- Completion date
- Jan 31, 2023
- First posted
- May 28, 2021
- Last posted
- May 28, 2021
- Enrollment
- 50
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Abbisko Therapeutics Co, LtdLead sponsor
- National Taiwan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.